文献速递心脑血管急症

替奈普酶用于卒中患者溶栓:系统评价与荟萃分析

Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-12-24
一句话结论替奈普酶与阿替普酶在3个月功能结局、颅内出血和死亡上无差异,但替奈普酶再通率和早期神经功能改善更高。

该系统评价与荟萃分析纳入8项观察性和实验性研究、共2031例接受溶栓的成人急性缺血性卒中患者,比较替奈普酶与阿替普酶。主要结果显示:两组3个月良好或极好功能结局无差异,但替奈普酶组再通率(ARD=0.11,95%CI 0.01–0.20)和早期神经功能改善(ARD=0.10,95%CI 0.02–0.17)更高;颅内出血、症状性颅内出血和死亡无差异。结论认为替奈普酶可作为阿替普酶的替代溶栓药物,具有更低成本和更有利的药代动力学特征(可弹丸式注射)。

要点

  • 替奈普酶组再通率较阿替普酶组绝对提高11%(ARD=0.11,95%CI 0.01–0.20),基于8项研究、2031例成人急性缺血性卒中溶栓患者。
  • 替奈普酶组早期神经功能改善较阿替普酶组绝对提高10%(ARD=0.10,95%CI 0.02–0.17)。
  • 两组3个月良好功能结局(ARR=0.07)和极好功能结局(ARR=0.03)均无统计学差异(p>0.05)。
  • 两组颅内出血(ARD=-0.02,95%CI -0.06–0.01)、症状性颅内出血(ARD=0.00,95%CI -0.01–0.02)和死亡(ARD=0.00,95%CI -0.03–0.03)均无差异。
  • 替奈普酶为基因修饰型阿替普酶,成本更低且可弹丸注射,药代动力学更有利。

适用人群与场景

  • 接受溶栓治疗的成人急性缺血性卒中患者(纳入8项观察性和实验性研究,共2031例)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 替奈普酶可弹丸式注射,但原文未提及具体剂量、单位、给药途径细节或目标值。
  • 阿替普酶为已批准的急性缺血性卒中溶栓治疗药物,原文未提及具体剂量方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入8项观察性和实验性研究,共2031例患者。
  • 干预与对照:替奈普酶 vs 阿替普酶。
  • 主要终点:3个月良好功能结局(ARR=0.07,p>0.05)和极好功能结局(ARR=0.03,p>0.05)均无差异。
  • 关键次要终点:再通率ARD=0.11(95%CI 0.01–0.20),早期神经功能改善ARD=0.10(95%CI 0.02–0.17),均利于替奈普酶。
  • 安全性:颅内出血ARD=-0.02(95%CI -0.06–0.01)、症状性颅内出血ARD=0.00(95%CI -0.01–0.02)、死亡ARD=0.00(95%CI -0.03–0.03),均无差异。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入观察性和实验性研究。
  • 局限:纳入研究为观察性和实验性混合设计,原文未提及具体偏倚风险或异质性评估。

对床旁实践的改变

  • 对于成人急性缺血性卒中溶栓患者,替奈普酶可作为阿替普酶的替代选择,再通率和早期神经功能改善可能更优,且不增加颅内出血或死亡风险。
  • 替奈普酶成本更低且可弹丸注射,可能简化给药流程,但原文未提供具体剂量方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Alteplase is an approved treatment for acute ischemic stroke. Tenecteplase is a genetically modified form of alteplase, with lower cost and a more favourable pharmacokinetic profile allowing bolus injection. The aim of this study was to compare both drugs in adult patients with acute ischemic stroke undergoing thrombolysis.

MATERIAL AND METHODS: PubMed and CENTRAL were searched for observational and experimental studies comparing both drugs in the population of interest. Additional studies were sought in clinical trial registries and by means of reference check. The efficacy outcomes of interest were functional status at 3 months, recanalization and early neurological improvement (ENI). The safety outcomes of interest were cerebral haemorrhage (ICH), symptomatic ICH and mortality. The effect measure of interest was the absolute risk difference (ARD). Effect measures for each outcome were pooled across studies using random effect models.

RESULTS: Eight studies were included, involving 2031 patients. Overall, there were no differences in terms of good or excellent functional outcome (ARR = 0.07 and 0.03 respectively, p > 0.05 for both comparisons) but tenecteplase patients showed higher rates of recanalization (ARD = 0.11, 95% CI [0.01;0.20]) and ENI (ARD = 0.10, 95% CI [0.02;0.17]). There were no differences between groups in terms of ICH (ARD = -0.02, 95% CI [-0.06;0.01]), symptomatic ICH (ARD = 0.00, 95% CI [-0.01;0.02]) or death (ARD = 0.00, 95% CI [-0.03;0.03]).

CONCLUSION: Tenecteplase is an alternative to alteplase for stroke thrombolysis, with lower cost and a more favourable pharmacokinetic profile.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Oliveira M, Fidalgo M, Fontão L, et al. Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis. Am J Emerg Med. 2020. PMID: 33440328. doi:10.1016/j.ajem.2020.12.026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。